(Q38977166)

8 September 2017

1 reference

title

The challenges of pharmacokinetic variability of first-line anti-TB drugs (English)

1 reference

8 September 2017

1 reference

3

Soumya Swaminathan

1 reference

8 September 2017

author name string

Bella Devaleenal Daniel

series ordinal

1

1 reference

8 September 2017

Geetha Ramachandran

series ordinal

2

1 reference

8 September 2017

language of work or name

English

0 references

publication date

11 October 2016

1 reference

Expert Review of Clinical Pharmacology

8 September 2017

published in

1 reference

8 September 2017

volume

10

1 reference

8 September 2017

issue

1

1 reference

8 September 2017

page(s)

47-58

1 reference

Eleven years of community-based directly observed therapy for tuberculosis

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Serum drug concentrations predictive of pulmonary tuberculosis outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Understanding pharmacokinetics to improve tuberculosis treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

New anti-tuberculosis drugs and regimens: 2015 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Effect of food on bioavailability of rifampicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Impact of food intake on the pharmacokinetics of first-line antituberculosis drugs in Taiwanese tuberculosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Therapeutic drug monitoring in the treatment of tuberculosis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics of anti-tuberculosis drugs in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Antiretroviral pharmacokinetics in the paediatric population: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Developmental pharmacology--drug disposition, action, and therapy in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics of intravenous rifampicin (rifampin) in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Single-dose pharmacokinetics of rifapentine in elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Isoniazid elimination kinetics in children with protein-energy malnutrition treated for tuberculous meningitis with a four-component antimicrobial regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pyrazinamide plasma concentrations in young children with tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Childhood tuberculosis - global epidemiology and the impact of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Journal of diabetes and metabolic disorders: launch editorial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Bi-directional screening for tuberculosis and diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Influence of Food on the Bioavailability of Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Chapter 7: Pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacogenomics of anti-TB drugs-related hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Therapeutic drug monitoring in the treatment of active tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Clinically significant interactions with drugs used in the treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetic interactions with rifampicin : clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacokinetic Interactions with Rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Clinical Pharmacokinetics of Isoniazid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1246179

10.1080/17512433.2017.1246179

21 January 2018

Identifiers

DOI

1 reference

release_tfx2enym35ai7l7raatc7ubkdy

8 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tfx2enym35ai7l7raatc7ubkdy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference